EGFR and non-small cell lung carcinoma: Studies that have evaluated EGFR amplification by in situ hybridization techniques have demonstrated benefits with either EGFR tyrosine kinase inhibitors (TKIs) or anti-EGFR mAb in non-small cell lung cancer (NSCLC) (52, 53).